We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take ...

Amvuttra – The Key Growth Driver for Alnylam Amvuttra sales contribute significantly to Alnylam’s top line. The drug generated sales worth $970.5 million in 2024, up 74% on a year-over-year basis.

Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like ...

FDA approved Alnylam's Amvuttra for ATTR-CM, making it the first treatment cleared for both ATTR-CM and hATTR-PN in adults. In trials, Amvuttra cut mortality risk by 36% through 42 months and ...

− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality ...

Alnylam Pharmaceuticals has landed a long-awaited FDA decision that expands use of its drug, Amvuttra, to the treatment of a type of cardiomyopathy that’s growing in prevalence. It’s the ...

The FDA has signed off on Alnylam’s Amvuttra, also known as vutrisiran, as a treatment for cardiomyopathy of wild-type or hereditary ATTR-CM in adults to reduce the chance of cardiovascular ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to treat protein ...

Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication. The drug was approved for treatment of the cardiomyopathy of wild-type ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability. Alnylam Pharmaceuticals ...

Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $268 from $284 and keeps an Equal Weight rating on the shares. The firm is ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its lead drug, Amvuttra (vutrisiran), for treating the cardiomyopathy of ...